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Background
During the past decade, human stem cells have been the
focus of an increased interest due to their potential in clin-
ical applications, as a therapeutic alternative for several
diseases. Within this context, human mesenchymal stem
cells (hMSCs) have gained special attention due to their
immune-modulatory characteristics, as well as in secreting
bioactive molecules with anti-inflammatory and regenera-
tive features [1].
In order to face the high demands of hMSCs (from 105
to 109 cells per patient) [2] to be used in therapies, the
establishment of robust manufacturing platforms that can
ensure the efficient production, purification and formula-
tion of stem cell-based products is still a challenge.
Although substantial efforts have been performed on the
development of clinical-grade bioprocesses for the expan-
sion of hMSCs in microcarrier-based stirred culture sys-
tems, the incorporation of downstream strategies that
assure efficient cell-bead separation and consequent
hMSC concentration (i.e. volume reduction) and washing
is required to deliver safe hMSCs to the clinic [3,4].
Therefore, the main aim of this work was the design
of integrated methodologies (filtration and membrane
technology approaches) [5] for the robust and clinical-
grade downstream processing of hMSC.
Materials and methods
Cell culture: hMSCs (STEMCELL Technologies™) were
cultivated in IMDM supplemented with 10% of fetal
bovine serum (FBS) or in MesenCult®-XF Medium
(STEMCELL Technologies™) supplemented with 2 mM
L-glutamine (Life Sciences) at 37°C in a humidified
atmosphere of 5% CO2, according to manufacture
recommendations. These cells were routinely propagated
in static conditions (T-flasks) or on microcarriers (Solo-
Hill Engineering, Inc) using stirred culture systems
(spinner vessels and bioreactors). Cell concentration and
viability were determined by counting the cells in a
hemacytometer using the standard trypan blue exclusion
method.
Cell characterization and quality control tests: Stan-
dard procedures for the analysis of cell surface markers
(CD90, CD73, CD45, CD34) using flow cytometry tools,
as well as cell-based assays for the evaluation of cell
proliferation capacity (CFU assay - colony-forming unit)
and differentiation potential (differentiation into osteo-
blasts and adipocytes) were performed, following the
manufacturer’s recommendations.
Downstream processing: After harvesting, the microcar-
riers were removed from the cell suspension using nylon
filters (Millipore) with different pore sizes (100, 80 and
30 μm). The clarified cell-based materials were concen-
trated by tangential flow filtration (TFF) using polysulfone
hollow-fiber cartridges with 0.45 μm pore size.
Results
Over the past years, as scale-up platforms for the bioma-
nufacturing of hMSCs become robust enough to yield
high cell quantities to support cell-based therapies, culture
media supplemented with FBS are becoming less used.
This requirement is in line with what is advised by regula-
tory agencies, due to the main drawbacks associated to the
use of FBS, such as the variability between different lots
and suppliers and the risk of contamination with animal
pathogens, which may trigger an immune response upon
MSC therapy [5]. Within this context, large efforts have
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been made towards the development of serum- and xeno-
free culture medium formulations for the expansion of
hMSC. Thus, on a first approach, we evaluated the feasi-
bility of propagating hMSCs in a serum- and xeno-free
culture medium, the MesenCult®-XF medium, and further
compared cell growth profile with standard medium for-
mulation (e.g. IMDM + 10% FBS). Our results showed
that, hMSC can be successfully expanded in MesenCult®-
XF medium, presenting a constant population doubling
length (PDL) of approximately 2 in each cell passage and
a cumulative PDL of 12.5 in a total of 42 days (Figure 1A).
Moreover, hMSCs showed an accelerated cell growth
and increased lifespan when compared to the hMSC
cultivated in standard culture medium supplemented
with FBS where hMSCs presented limited proliferation
capacity (Figure 1A). This was an expected outcome since
MesenCult®-XF medium was design to enhance hMSC
expansion from primary human bone marrow and cul-
tured-expanded cells, leading to long-term cultures. It is
important to mention that hMSCs maintained their char-
acteristics after expansion in MesenCult®-XF medium,
namely immunophenotype, proliferation capacity and
multipotency (results not shown).
After the expansion of hMSCs in microcarrier-based
stirred culture systems, different downstream strategies
were evaluated for the purification of hMSCs. First, the
clarification step was carried out to remove the microcar-
riers from the cell suspension. For this purpose, nylon
filters were used and the effect of the mesh pore size on
cell recovery yields and viability was evaluated. Our
results showed that nylon is a suitable material for the
clarification step since it ensured efficient removal of
microcarriers (no beads were detected after filtration pro-
cessing) without compromising cell viability (Figure 1B).
Moreover, we demonstrated that higher mesh pore sizes
yielded higher cell recoveries (Figure 1B).
For the cell concentration and volume reduction step,
preliminary experiments were performed with human
foreskin fibroblasts (Figure 1C). With this cellular system,
a concentration factor (in volume) of 10 times was suc-
cessfully achieved using TFF processes, yielding 70-80%
of recovered cells with high viabilities (Figure 1C).
Figure 1 Up- and down- stream processing of hMSCs. A) Growth profile of hMSC culture; profile of cumulative PDLs of hMSC cultured in
MesenCult®-XF (blue line) or in IMDM + 10% FBS (purple line) medium along culture time. B) Microcarriers’ removal using nylon filters with
different pore sizes (100, 80 and 30 μm). The (blue) bars represent the cell recovery yields, while the (green) line represents cell viability. C) Major
outcomes achieved after TFF processing of human foreskin fibroblasts and hMSCs.
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Process validation with hMSCs is ongoing but first
results were encouraging since we were able to concen-
trate 2 times hMSCs while ensuring high cell recovery
yields (96%) and viabilities (98%) (Figure 1C). In addition,
hMSCs maintained their immunophenotype, as well as
their proliferation capacity and multilineage differentia-
tion potential at the end of all steps of the downstream
process (results not shown).
Conclusions
While upstream technologies mature to meet the increas-
ing demand of hMSCs, biomanufacturing bottlenecks are
now shifting towards the downstream processing of stem
cells. This work shows our first approach to tackle such
bottlenecks. More specifically, we demonstrate that stan-
dard filtration techniques and TFF systems are suitable
and robust approaches for the downstream processing of
hMSCs. Using these strategies we were able to ensure
efficient removal of the major impurities of the cellular
suspension (microcarriers) and further concentrate cell-
based products up to 10 times without compromising
their viability and quality. However, further improve-
ments in cell concentration and polishing steps are still
required. Nonetheless, this work provides important
insights towards the establishment of robust and clinical-
grade bioprocesses for the purification of hMSCs to be
integrated and applied in the biomanufacturing of cell-
based therapies.
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